Clinical Trial Update: Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol [Phase 3]

View source ↗

Summary

Phase 3 trial recruiting to evaluate solriamfetol's effects on binge eating disorder by modulating TAAR-1, dopamine, and norepinephrine pathways.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder

Drugs mentioned

• Solriamfetol (solriamfetol)

Snippet

Sponsor: Axsome Therapeutics, Inc. | Conditions: Binge-Eating Disorder | Phase 3 | Status: RECRUITING